Drug intelligence / Profile preview

HcHAb18

Development stage: Phase 1
Lead developer: Jiangsu Pacific Meinok Biopharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

HcHAb18 is a humanized monoclonal antibody directed against CD147 (also known as Basigin or EMMPRIN), a cell surface glycoprotein that is highly expressed in many solid tumors, including non-small cell lung cancer (NSCLC). CD147 is involved in promoting tumor cell proliferation, apoptosis resistance, and the induction of matrix metalloproteinases (MMPs) which facilitate extracellular matrix degradation and metastasis. By binding to CD147, HcHAb18 aims to block these oncogenic pathways. The drug was developed by Jiangsu Pacific Meinuoke Biopharmaceutical and has been investigated in early-phase clinical trials for safety and preliminary efficacy in patients with advanced NSCLC.

Other names: humanized HAb18 monoclonal antibodyHAb18HAb-18HAb 18

Targets

BSG (Basigin)

Beyond the preview

Go deeper on HcHAb18.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HcHAb18.